Clinical
New clinical trial registered for Lutetium Lu-177 Vipivotide Tetraxetan
Related compound: Lutetium Lu-177 Vipivotide TetraxetanView source →
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer (NCT05818683) registered on ClinicalTrials.gov. Phase: phase 1. Status: recruiting.